TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03550118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable socket
Description: The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
Study: NCT04504422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS was applied for 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea).
Study: NCT00543257

Intervention type: OTHER
Intervention: Use of paper forms to write down information
Description: Parents will be asked to write down information specific to their child's ADHD using paper forms.

Intervention type: OTHER
Intervention: Computer
Description: Parents will use a computer to complete data entry on information specific to their child's ADHD care
Study: NCT00189540

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HGF plasmid
Description: Intramuscular injections into the index leg on days 0, 14, and 28

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injections into the index leg on days 0, 14, and 28
Study: NCT00690729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Bibliotherapy
Description: Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Therapist-directed exposure and response prevention
Study: NCT06316908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Neurolytic Celiac Plexus Block with Absolute Alcohol
Description: Participants assigned to the unilateral neurolytic celiac plexus block group underwent a minimally invasive procedure where a solution of absolute alcohol was injected unilaterally into the celiac plexus under image guidance. The procedure was performed by an experienced interventional pain specialist. Prior to the injection, local anesthesia was administered to minimize discomfort. Once positioned correctly, a needle was inserted into the designated area, and a small amount of absolute alcohol was injected to disrupt the neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide long-term pain relief for participants suffering from chronic abdominal pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Neurolytic Celiac Plexus Block with Absolute Alcohol
Description: Participants allocated to the bilateral neurolytic celiac plexus block group underwent a similar minimally invasive procedure as described above, with the exception that the injection of absolute alcohol was administered bilaterally into the celiac plexus. The procedure was performed by an experienced interventional pain specialist under image guidance, with local anesthesia administered prior to the injection to ensure patient comfort. Following correct needle placement, absolute alcohol was injected into both sides of the celiac plexus to disrupt neural pathways responsible for transmitting pain signals from the abdominal region. The intervention aims to provide comparable or potentially enhanced long-term pain relief compared to the unilateral approach, with the additional benefit of targeting both sides of the celiac plexus.
Study: NCT01746368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Nurse-Supported Advance Care Planning Intervention
Description: This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-as-Usual
Description: The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
Study: NCT00984984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone PO
Description: 10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone IV
Description: IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
Study: NCT02728115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD Lower Dose
Description: The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD Higher dose
Description: The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
Study: NCT02051452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01119053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS Pulse Model 102
Description: Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VNS Pulse Model 102
Description: Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
Study: NCT03584750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Floating
Description: Floating in specialized tank with full floatation and sensory deprivation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo floating
Description: Floating in specialized tank with reduced floatation and sensory deprivation.
Study: NCT02775188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interACTION

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Physical Therapy
Study: NCT00920751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water infusion
Description: Water infusion in lieu of air insufflation during colonoscope insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Conventional air insufflation colonoscopy
Study: NCT01882673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Computer Motivational Interviewing for Smoking Cessation
Description: Brief computer motivational interviewing intervention to motivated tobacco quitline use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Control
Description: Computer delivered nutrition education control condition
Study: NCT03543761

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dornier Aries 2 device
Description: • Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries 2 device
Description: LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries 2 device
Description: LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
Study: NCT01339689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: 200-600 mg bid, capsules, up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules, bid, up to 12 weeks
Study: NCT04361370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib-Pembrolizumab-Bevacizumab
Description: * Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)
Study: NCT04260685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: IV bolus of 1.5mg/kg lidocaine 1% followed by continuous infusion of 1.5mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: IV bolus of esmolol 0.5 mg/kg followed by continuous infusion of 100-300 ug/kg/min
Study: NCT03169166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
Study: NCT00057863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03284606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAPING
Description: Taping in conjunction with common rehabilitation for hemiplegic patients

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Common rehabilitation
Description: Common rehabilitation for hemiplegic patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Common rehabilitation
Description: Common rehabilitation for hemiplegic patients
Study: NCT03547778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 mcg pesssary
Description: Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
Study: NCT00082498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH-D (vicriviroc)
Description: Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH-D (vicriviroc)
Description: Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH-D (vicriviroc)
Description: Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in Group 1 will receive placebo.
Study: NCT04610359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-MC-01
Description: Submucosal injection of 2.0 x 10,000,000/5ml (1mL \* 5 sites)
Study: NCT02016196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~--------------------------------------------------------------------------------

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
Study: NCT01320358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECMPS-IEM
Description: ECMPS-IEM
Study: NCT03186612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OT+VR intervention with videogames for the upper limb (dexterity)
Description: Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OT+VR intervention with videogames for the upper limb (dexterity)
Description: Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
Study: NCT03936998

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vancomycin plus VE416 before PNOIT
Description: Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vancomycin plus VE416 with PNOIT
Description: Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
Study: NCT01949038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral alprazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual alprazolam
Study: NCT03936998

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo plus VE416 with PNOIT
Description: Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus placebo with PNOIT
Description: Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
Study: NCT01210716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic plasma exchange
Description: Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
Study: NCT02444429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid boluses Methylprednisolone
Description: Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No therapeutic modification
Description: No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No therapeutic modification
Description: No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop maintenance corticotherapy
Description: Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
Study: NCT02591810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial casting/splinting
Description: Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous fixation
Description: Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foveal repair
Description: Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
Study: NCT01949038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual placebo
Study: NCT00184795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Description: One tablet per day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)
Description: One tablet per day for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets for 24 weeks
Study: NCT02055326

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Smoking Cessation
Description: one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: One hour, twice weekly for 8 weeks of vinyasa yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health & Wellness
Description: Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
Study: NCT03599206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.